CER Daily Newsfeed

Video: SCOPE Summit 2025: Graham Clark on Ensuring Data Consitency Amid the Rise of Real-World Evidence

(2/21, Don Tracy, Applied Clinical Trials) reports “In an interview with Applied Clinical Trials Associate Editor Don Tracy, Graham Clark, CEO, Phastar, discusses key objectives for attending SCOPE, the rise of real-world evidence, and partnerships critical to improving the success of clinical trial outcomes.” View Video

Trump CMS Offers Defense Of IRA In First Appellate Brief

(2/20, Gabrielle Wanneh, Inside Health Policy) reports “...Michael Lieberman, an attorney at Fairmark Partners who has helped the advocacy group Patients for Affordable Drugs file amicus briefs supporting the IRA, told Inside Health Policy CMS’ defense of the law is a positive indication the Trump administration will continue to defend the IRA’s constitutionality against industry attacks, and shows how carefully lawmakers considered and wrote the law’s directions for implementing price negotiations.” Subscription Required

Medicare’s Drug Price Negotiation And Innovation: What’s Off The Table Matters Too

(2/21, Feng Xie, Brittany Humphries, Health Affairs Forefront) comments “...For small biotech companies that decide to commercialize, the criteria of the single source drug consisting of ‘80 percent or more of the Medicare program expenditures for the manufacturer’ may cause further disincentive for innovation. These companies likely do not have another blockbuster drug, and having a single product is a vulnerable time for them. They may seek to build their portfolio in other ways.” Full

Secretary Kennedy: You Cannot Spell MAHA Without AHRQ

(2/20, Madison Haiman, M.S.W., Josh Caplan, M.A., M.P.P., AcademyHealth Blog) comments “...Secretary Kennedy and the Make America Healthy Again Commission can improve health outcomes by leveraging AHRQ’s research into chronic diseases, low-value care, and barriers to health care access. AHRQ is efficient and practical, providing transparent, evidence-based insights that help policymakers and health systems make informed decisions. It focuses on improving health care quality, effectiveness, and accessibility through health services research, the science that determines what works, how, for whom, and at what cost.” Full

Harmonisation Health Technology Assessments, a Slow Roll in Right Direction

(2/21, Aneta Zachová and Filip Áč, Euractiv) reports “...Despite its challenges, the national HTA agencies widely endorse and approve the regulation. ‘Member States of the Beneluxa Initiative have played key roles in supporting its introduction. The Initiative will work to incorporate the joint assessments into joint work on pricing and reimbursement,’ the Beneluxa Initiative, a pharmaceutical policy initiative uniting Belgium, the Netherlands, Luxembourg, Austria, and Ireland, told Euractiv.” Full